Jiangsu Hengrui Pharmaceuticals (01276) reported net profit attributable to shareholders of approximately RMB6.923 billion for the first three quarters, up 20.38% year on year.

Jiangsu Hengrui Pharmaceuticals (01276) announced its results for the first three quarters of 2026, with revenue of approximately RMB24.409 billion, up 5.26% year on year; net profit attributable to shareholders of the listed company of approximately RMB6.923 billion, up 20.38% year on year; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses of RMB6.243 billion, up 11.70% year on year; and basic earnings per share of RMB1.05. The company continued to step up innovation and maintained a high level of R&D investment, with cumulative R&D investment of RMB7.146 billion in the first three quarters of 2026, of which RMB5.423 billion was expensed. In the first three quarters of 2026, the company's innovative drug sales revenue was RMB13.871 billion, up 17.05% year on year, accounting for 64.59% of pharmaceutical sales revenue, up from the prior level. Within innovative drug sales revenue, revenue from anti-tumor innovative products was RMB9.865 billion, up 3.13% year on year, accounting for 71.12% of total innovative drug sales revenue. Revenue from non-tumor innovative products was RMB4.006 billion, up 75.36% year on year, accounting for 28.88% of total innovative drug sales revenue. In the first three quarters of 2026, the company recognized revenue of RMB2.781 billion from outbound licensing of innovative drugs, up 31.12% year on year, mainly consisting of revenue recognized by GSK and BMS based on the progress of completion of performance obligations and milestone payments for certain licensed products; the company received cash of RMB4.343 billion in upfront and milestone payments from outbound licensing collaborations, mainly the US$600 million upfront payment from BMS.